ADC Therapeutics SA (ADCT) Appoints Jean-Pierre Bizzari to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- BofA raises hyperscaler AI capex outlook to $3.6tn through 2028
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
July 1, 2022 7:15 AM EDTAmeet Mallik, Chief Executive Officer of ADC Therapeutics, also joins the Board
LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of veteran oncology drug developer Jean-Pierre Bizzari, MD, to its Board of Directors. Additionally, Ameet Mallik, who was appointed as the Companys Chief Executive Officer in May 2022, will join the Board.
This press release features multimedia. View the full release here:... More
